Pangu BioPharma, a subsidiary of aTyr Pharma, is a leading biopharmaceutical brand based in Hong Kong. With a strong focus on tRNA synthetase biology, Pangu collaborates with the esteemed Hong Kong University of Science and Technology (HKUST) to support basic and translational research. Their team of expert researchers, specializing in molecular biology, genetics, and protein structure, has made significant advancements in identifying and characterizing naturally occurring splice variants of human amino-acyl tRNA synthetases.

Pangu's work in this field has been financially supported by the Hong Kong government's Innovation and Technology Commission (ITC). As part of aTyr Pharma, Pangu contributes to the discovery and development of groundbreaking medicines rooted in novel immunological pathways. With a solid intellectual property estate encompassing 20 tRNA synthetase genes, aTyr Pharma's research focuses on the therapeutic translation of the Resokine pathway.

Notably, their clinical-stage candidate, Efzofitimod (ATYR1923), shows promising potential in down-regulating immune engagement in interstitial lung diseases and other immune-mediated conditions. To learn more about Pangu BioPharma and aTyr Pharma's innovative initiatives, visit their official website at www. atyrpharma.

com